10,000 doses available for interested providers and practices.
10,000 doses of HEPLISAV-B, an adult vaccine to protect against Hepatitis B, have been donated by biopharmaceutical company Dynavax and are available for healthcare workers on the frontline of the COVID-19 response.
Humanitarian aid organization Direct Relif is administering the dosages.
Hepatitis B, spread through the potentially deadly virus spread through percutaneous or mucosal contact with infections blood or body fluids, can survive outside the body and remain infectious for at least seven days, according to the CDC.
If symptoms occur, they begin between 60 to 150 days after exposure, says the CDC.
“The risk of deadly, blood borne pathogens, like hepatitis B, are greatly increased due to the strained operational and infrastructure issues and rapid deployment of surge healthcare professionals into a stressed environment. With a heightened focus on the respiratory transmission of COVID-19, there is the potential to overlook typical precautions in the emergency setting,” said Arun Jesudian, MD, assistant professor of medicine at New York-Presbyterian Hospital - Weill Cornell Medicine in a statement.
Interested healthcare providers and facilities can visit DirectRelief.org/apply to learn more about accessing the donated supply.